Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04222972
Title A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Blueprint Medicines Corporation
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Carboplatin + Paclitaxel + Pembrolizumab

Carboplatin + Nab-paclitaxel + Pembrolizumab

Pralsetinib

Cisplatin + Gemcitabine

Carboplatin + Gemcitabine

Cisplatin + Pemetrexed Disodium

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL

Additional content available in CKB BOOST